Published on
December 19, 2024
- 16:45 GMT
Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in Pancreatic Cancer
The expanded phase 1 clinical trial is using serial biopsies and blood samples to analyze the tumor response to RMC-6236 at an unprecedented level of detail. CAMBRIDGE, MA, UNITED STATES, December 23, 2024 /EINPresswire.com/ -- – Break Through Cancer …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Science
...
